Background
==========

Systemic mastocytosis (SM) rarely occurs in combination with so called "associated clonal haematological non-mast cell lineage disease" (AHNMD) \[[@B1]-[@B5]\]. In most instances, the AHNMD component is of myeloid origin, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) or primary myelofibrosis (PMF) \[[@B1],[@B6]-[@B8]\]. Recently, *KIT*^D816V^ mutations were identified in both disease components of SM-AHNMD with the highest frequency in SM-CMML \[[@B9]\], suggesting a common precursor.

Methods and findings
====================

We report on a 73 year old male patient who was initially diagnosed with CMML. Untreated for three years, extended investigations for disease progression showed a normal karyotype and neither a JAK-2 mutation nor a BCR-ABL fusion gene. Due to abnormal BM mast cell infiltrates the patient met the WHO 08 \[[@B1]\] criteria for SM-CMML with proven *KIT*^D816V^ mutation in different cell subpopulations as detailed in (Figure  [1](#F1){ref-type="fig"}A-D). The patient died of disease under treatment with azacitidin (vidaza^®^) four months after this diagnosis. Autopsy findings showed additionally to the bone marrow involvement widespread disease in different extramedullary haematopoietic and visceral organs. There was no transformation into acute leukemia.

![**Assessment of the*KIT***^**D816V**^**mutation on the bone marrow trephine. A***upper line*: HE stain of the bone marrow trephine showing both, CMML and SM part in distinct areas in this patient (left). A CD117 immunostain (right) highlights the mast cells in the SM compartment, however cells within the CMML compartment are negative. *Lower line*: HE control before and after punching out the SM area (containing around 90% of MC in the CD117 staining) submitted to PCR and Sanger Sequencing. **B** Forward and reverse sequences indicating the *KIT*^D816V^ mutation of microdissected SM area of the bone marrow trephine. **C** FACS sorted cells as indicated with a purity of around 90% for CD34+ stem cells and granulocytes. **D** Shows the sequencing results of the PCR amplification product for *KIT*^D816V^, and forward strands for isolated cell-subpopulations respectively.](2162-3619-3-18-1){#F1}

We applied a cancer gene panel containing 427 genes, custom-designed to include all exons of these genes on a solid capture array by NimbleGen (Roche). Captured targets (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1) were deep-sequenced on a GS 454-Junior (Roche) revealing 1033 gene variants with a mean coverage of 10-fold. The analysis with the GS Reference Mapper software v.2.5 (Roche; default settings and hg19 as reference genome) identified, next to the successfully verified *KIT*^D816V^ mutation, sixty-four (6%) variants in the coding region of 42 genes (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). Of the 64 variants, 61 (95%) were single nucleotide polymorphisms. The remaining were two as yet unreported SNVs (*CBFA2T3* and *CLTCL1*) and one 1-bp deletion (*BLM;* COSM252959). All three mutations were confirmed by Sanger sequencing (Genetic Analyzer 3130xl (Applied Biosystems); \[[@B10]\]) using DNA from PB, the SM part of BMT and normal tissue, meeting the criteria for germ-line mutations (representative sequences in Figure  [2](#F2){ref-type="fig"}A). Since, however, the assumed 1-bp deletion of *BLM* at AA515del1 -- Asn515fs\*16 could be identified in a non-tumoral human embryonic kidney cell line (HEK293T), we interpreted this aberration as a PCR/sequencing artefact associated with a mononucleotide repeat at this site. This finding was additionally confirmed by sub-cloning of the PCR-product in a bacterial expression vector and sequencing with different primer sets (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S1). Interestingly, previous reports describe exactly the same deletion in gastrointestinal cancer and in T-ALL cell lines \[[@B11],[@B12]\].

![**Verification of identified variants by Sanger sequencing. A**: Representative sequences of *CBFA2T3*, *CLTCL1,* and *BLM* using DNA derived from the SM part of BMT, PB, and the SM part of BMT, respectively. **B**: Sequencing of *TET2* and *RUNX1* using DNA derived from PB, the SM part of BMT, and normal tissue. **C**: Sequencing of *TET2* and *RUNX1* using DNA derived from FACS sorted PB cell populations.](2162-3619-3-18-2){#F2}

To achieve a higher resolution we performed a high coverage targeted re-sequencing with identical blood derived DNA using the Ion AmpliSeq™ Comprehensive Cancer Panel comprising all exons of 409 known cancer genes (Life Technologies). Forty ng DNA was used as input and the target regions were 13-fold PCR amplified. After ligation of Torrent specific adapters, the amplicons were subjected to clonal expansion on spheres using the Ion One Touch 2 system (Life Technologies). Subsequently, the amplicons were dispersed on a PI chip and sequenced on the Ion Proton platform \[[@B13]\]. Mean coverage was 1674-fold whereas more than 93% of the amplicons were covered at least 100-fold and more than 81% at least 500-fold allowing sensitive variant detection. Alignment (hg19), local re-alignment (2-fold), and probabilistic variant detection (90% probability and 10-fold coverage) were performed using CLC Genomics Workbench version 5.5. Additional filtering resulted in variants with following characteristics: i) non-synonymous variants and INDELs resulting in frame-shifts, ii) phred-score \> = 20 and variant coverage \> = 50x, and iii) forward/reverse read ratio \> = 0.25. These filter criteria resulted in identifying 177 variants (Additional file [4](#S4){ref-type="supplementary-material"}: Table S3). From these, 144 were present in the 1000 Genome database and dbSNP and were therefore excluded in the following analysis. Under additional more stringent filtering criteria for 1-bp INDELs in homopolymeric regions (CLC default settings for 454/Ion) a final list of 11 variants emerged (Additional file [5](#S5){ref-type="supplementary-material"}: Table S4) including *KIT*^D816V^. Interestingly, variants of two genes previously described in SM-AHNMD \[[@B14]\]*TET2* (p.Thr1027fs, p.Cys1263Ser) and *RUNX1* (p.Asn109Ser) were detected. Although detectable by the 454-Junior, their coverage was too low to be called by the GS Reference Mapper. Of note, 44 variants of the 64 variants identified by the 454-Junior/GS Reference Mapper platform lay in target regions of the CCP (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). From these, 35 were verified by the Ion Torrent/CLC platform, one was differently aligned, and eight were not detected.

Thus, the variants in *TET2* and *RUNX1* represented most probably true positive calls potentially involved in SM-CMML pathogenesis. Although, they have not yet been reported in the Cosmic database, the mutations highly likely influence the protein function: i) the frame-shift mutation in *TET2* occurring in front of the two conserved regions of TET2 (1104--1478, 1845--2002) and the SNV lying within the first region \[[@B15]\], ii) the mutation in RUNX1 located in the RUNT domain which is responsible for proper DNA binding and heterodimerization \[[@B16]\].

The 2-bp insertion (p.Thr1027fs) and the SNV (p.Cys1263Ser) in *TET2*, and the SNV (p.Asn109Ser) in *RUNX1* were confirmed in PB and the SM part of BMT (Figure  [2](#F2){ref-type="fig"}B). Very low signals of the variants were detected in normal tissue, most probably due to infiltrating mast cells. Whereas no signals were found in B- and T-lymphocytes, similar signal intensities for both *TET2* mutations were seen in CD34+ precursor cells and CD16+ granulocytes comparable to the signals in the SM part of BMT (Figure  [2](#F2){ref-type="fig"}C). In contrast, *RUNX1* exhibited a double intensity of the variant in CD34+ cells compared to the SM part of BMT and a homozygous variant signal in granulocytes.

Inasmuch the SNPs and seven variants identified (Additional file [5](#S5){ref-type="supplementary-material"}: Table S4) are implicated in the disease development needs to be confirmed. Importantly however, we present an in-depth analysis of the sub-clonal relation of SM-CMML which reveals essential concomitant key mutations in *KIT*, *TET2*, and *RUNX1* in the emergence of different disease compartments. Since the mutant allelic fraction in the blood of *KIT* (0.44), *TET2* (0.45, 0.44), and *RUNX1* (0.53) assessed by NGS (Proton platform) were in a similar range (Additional file [5](#S5){ref-type="supplementary-material"}: Table S4), we assume that these mutations belong to the same CD34+ sub-clonal cell population. This is supported by the fact that the electropherograms of the Sanger sequencing exhibited the same intensities for *KIT* and *TET2* mutations in blood and the SM-area as well as in the sorted CD34+ and granulocytic cell fraction (Figure  [2](#F2){ref-type="fig"}). Additionally, *RUNX1* mutant signals assessed by Sanger sequencing were highest in the granulocytic cell fraction and balanced with wild-type in the SM-area (purity 90%) which implies that an additional LOH of *RUNX1* occured in a CD34+ mast cells precursor. This is as well reflected by the fact that the mutant allelic fraction of *RUNX1* (0.53) in the blood assessed by NGS (Proton platform) was increased by 0.09 in comparison to the other three SNVs (mean mutant allelic fraction *KIT*, 2x *TET2*: 0.44). Since the KIT (CD117) protein is expressed in the SM, but not in the CMML compartment (Figure  [1](#F1){ref-type="fig"}) ascribes the *KIT*^D816V^ mutation a pivotal role in the disease initiation, particularly of the SM fraction. Whereas *TET2* and *RUNX1* were necessary sequential mutations for progression to overt SM, homozygous loss of wild-type *RUNX1* seemingly was the driver mutation enabling a clonal expansion of the CMML lineage as suggested by our *disease model* (Figure  [3](#F3){ref-type="fig"}). This further underlines the concept of common tumour progenitor cells leading to a spectrum of the same disease rather than two different ones as the term SM-AHNMD evokes. The presence of *RUNX1* and *TET2* mutations in mature granulocytes and in MC of the BMT in our study is quite novel, since so far only one recent study showed concomitant mutations of *KIT* and *TET2* in mast cells and granulocytes in SM-AHNMD \[[@B14]\]. The increased number of driving-mutations could explain the rapid clinical progression in our patient and is in line with the previous study, advocating additional molecular aberrations a prognostic role \[[@B14]\].

![Hypothetical disease model of SM-CMML pathogenesis.](2162-3619-3-18-3){#F3}

In summary, the current SM-CMML derived from the same mutated tumour progenitor cells (*KIT* SNV, *TET2* frame-shift, *TET2* SNV, *RUNX1* SNV) which acquired additional mutations (i.e. *RUNX1* wild-type loss) in different sub-clones as hypothesised in our model to finally manifest in the pathological state of SM-CMML.
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